Nevertheless, more detailed and mechanistic comparison of the resistance not only to bevacizumab but also to membrane‐permeable receptor tyrosine kinase inhibitors targeting VEGF (e.g., sunitinib) could give further insights not only into EV‐resistance mechanisms but also into tumor biology and primary resistance to receptor tyrosine kinase inhibition. The gene discussed is NTRK1; the disease is neoplasm.